Furthermore, patients receiving PD-1 or PD-L1 inhibitors that have high polygenic risk score for hypothyroidism are reported to have longer survival but also a higher risk of hypo- and hyperthyroidism as well as vitiligo39. The gene discussed is CD274; the disease is hypothyroidism.